FOLH1 and prostate carcinoma: This study, however, indicates that in the murine model of prostate cancer tumors, at relatively lower activity levels, 177Lu-PSMA-NARI-56 demonstrates superior therapeutic efficacy and higher survival rates compared to 177Lu-PSMA-617.